Sinopharm began Phase III trials in Peru starting with two dozen people, with the goal to vaccinate 6,000 people between the ages of 18 and 75. So far, Sinopharm has given 30,000 doses to volunteers and another 10,000 participants have received double doses in Bahrain and the United Arab Emirates, with additional trials planned for Morocco and Argentina.